Author

Ingo Schwaner

Observed names: I Schwaner, I. Schwaner, Ingo SCHWANER, Schwaner Ingo, Schwaner, I., Schwaner, Ingo, Schwaner, Ingo (Dr. med.)

Observed institutions: F. Hoffmann-La Roche AG, Medizinische Hochschule Hannover, Humboldt-Universität zu Berlin, Klinikum Lüdenscheid, Klinikum Bielefeld, MVZ - Kurfürstendamm, Stiftung Charité, Freie Universität Berlin, Charité – Universitätsmedizin Berlin

ORCID: 0000-0001-8865-7282

Observed ORCID: 0000-0001-8865-7282

OpenAlex ID: A5023612723

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 587

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

2014 · Helmut Oettle, Hanno Riess, et al. · Journal of Clinical Oncology · 487

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

2011 · Uwe Pelzer, Ingo Schwaner, et al. · European Journal of Cancer · 370

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.

1995 · J Beyer, N Schwella, et al. · Journal of Clinical Oncology · 269

Allogeneic Dendritic Cells Fused with Tumor Cells: Preclinical Results and Outcome of a Clinical Phase I/II Trial in Patients with Metastatic Renal Cell Carcinoma

2003 · Angela Märten, Sabine Renoth, et al. · Human Gene Therapy · 147

A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study

2008 · U. Pelzer, K. Kubica, et al. · Journal of Clinical Oncology · 127

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

2013 · S. Kubicka, R. Greil, et al. · Annals of Oncology · 104

PDF

Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003)

2005 · H. Oettle, U. Pelzer, et al. · Journal of Clinical Oncology · 90

Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.

1996 · N Schwella, J Beyer, et al. · Journal of Clinical Oncology · 85

FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study

2023 · Sebastian Stintzing, Kathrin Heinrich, et al. · Journal of Clinical Oncology · 69

PDF

Histamine increases cytosolic Ca2+ in HL-60 promyelocytes predominantly via H2 receptors with an unique agonist/antagonist profile and induces functional differentiation.

1992 · R Seifert, A Höer, et al. · Molecular Pharmacology · 59

Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy

1997 · J�rg Beyer, Dorothea Kingreen, et al. · Cancer · 58

PDF

Mastoparan may activate GTP hydrolysis by Gi-proteins in HL-60 membranes indirectly through interaction with nucleoside diphosphate kinase

1994 · J F Klinker, A Hagelüken, et al. · Biochemical Journal · 54

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)

2018 · Dominik Paul Modest, Ludwig Fischer von Weikersthal, et al. · Journal of Clinical Oncology · 50

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

2022 · Sibylle Loibl, Chiun-Sheng Huang, et al. · npj Breast Cancer · 44

PDF

The H1 receptor agonist 2-(3-chlorophenyl)histamine activates Gi proteins in HL-60 cells through a mechanism that is independent of known histamine receptor subtypes.

1994 · R Seifert, A Hagelüken, et al. · Molecular Pharmacology · 43

PDF

Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

2021 · Sebastian Stintzing, Kathrin Heinrich, et al. · Journal of Clinical Oncology · 37

Receptor-mediated increases in cytosolic Ca2+ in the human erythroleukaemia cell line involve pertussis toxin-sensitive and -insensitive pathways

1992 · I Schwaner, R Seifert, et al. · Biochemical Journal · 36

PDF

Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: Evidence from phenotyping after rituxan therapy and transfectant cell analyses

2001 · Stefan Serke, Ingo Schwaner, et al. · Cytometry · 34

Generation of specific antibodies against the rap1A, rap1B and rap2 small GTP‐binding proteins

1992 · Franz‐Josef KLINZ, Roland SEIFERT, et al. · European Journal of Biochemistry · 34

Differential activation of Gi and GS proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL

1995 · Ingo Schwaner, Stefan Offermanns, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 33

PDF

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts

2011 · P C Thuss-Patience, A Kretzschmar, et al. · British Journal of Cancer · 23

PDF

96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE

2020 · S. Loibl, C-S. Huang, et al. · Annals of Oncology · 20

PDF

High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study

1997 · S Kleiner, A Kirsch, et al. · Bone Marrow Transplantation · 20

A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003

2007 · H. Riess, U. Pelzer, et al. · Journal of Clinical Oncology · 19

Works count: 81

Citation count: 3,050

H-index: 22

I10-index: 30